Discontinuation of Long-Term Clopidogrel Therapy Is Associated With Death and Myocardial Infarction After Saphenous Vein Graft Percutaneous Coronary Intervention  by Sachdeva, Amit et al.
Journal of the American College of Cardiology Vol. 60, No. 23, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00CLINICAL RESEARCH Interventional Cardiology
Discontinuation of Long-Term Clopidogrel Therapy Is
Associated With Death and Myocardial Infarction
After Saphenous Vein Graft Percutaneous
Coronary Intervention
Amit Sachdeva, MD,* Sumati Bavisetty, MD,* Gerald Beckham, MD,† Albert Y.-J. Shen, MD, MS,†
Vicken Aharonian, MD,† Prakash Mansukhani, MD,† Gregg W. Stone, MD,‡ Martin Leon, MD,‡
Jeffrey Moses, MD,‡ Naing Moore, MD,† Ric Hyett, BS,† Richard Contreras, MS,§
Somjot S. Brar, MD, MPH*†§
Los Angeles and Pasadena, California; and New York, New York
Objectives This study sought to examine the pattern of death and myocardial infarction (MI) after clopidogrel cessation in
patients undergoing percutaneous coronary intervention (PCI) of the saphenous vein graft (SVG).
Background The timing and incidence of adverse events by different durations of clopidogrel therapy after SVG PCI remain
unknown.
Methods This is a cohort study of patients undergoing SVG PCI between 2000 and 2009, followed for all-cause mortality
or MI after stopping clopidogrel. Incidence rates were calculated across different time periods after clopidogrel
cessation. Adjusted incidence rate ratios (IRR) were calculated with multivariable regression (piecewise exponen-
tial and Poisson).
Results There were 603 patients who underwent SVG PCI, of which 411 were event-free at the time of clopidogrel cessa-
tion. The incidence rate (95% confidence interval: [CI])/1,000 person-days of death or MI after stopping clopi-
dogrel in the time intervals of 0 to 90 days, 91 to 365 days, and 1 to 2 years were 1.26 (95% CI: 0.93 to 1.70),
0.41 (95% CI: 0.30 to 0.56), and 0.41 (95% CI: 0.30 to 0.55), respectively. In multivariable analyses, the overall
IRR (95% CI) for death or MI in the 0- to 90-day interval after stopping clopidogrel compared with the 91- to
365-day interval was 2.58 (95% CI: 1.64 to 4.07). Similar results were observed over a broad range of clopi-
dogrel treatment durations (6 months, 6 months to 1 year, 1 to 2 years, or 2 years). The results were also
consistent across subgroups, including sex, stent type, stent diameter, PCI period, and diabetes status. When
death alone was evaluated, there remained a significant increase in the event rate in the 0- to 90-day interval
compared with the 91- to 365-day interval (IRR: 2.33; 95% CI: 1.32 to 4.11).
Conclusions A clustering of events was observed in the initial 0 to 90 days after clopidogrel cessation in all treatment dura-
tions of clopidogrel investigated after SVG PCI. These results might have important implications in high-risk co-
horts undergoing PCI. Additional studies are needed to elucidate the mechanisms underlying the early clustering
of events after clopidogrel cessation. (J Am Coll Cardiol 2012;60:2357–63) © 2012 by the American College
of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.014Saphenous vein grafts (SVG) remain the commonest con-
duits used in surgical revascularization for severe coronary
atherosclerosis. However, SVG patency after coronary ar-
tery bypass grafting remains suboptimal; in a large random-
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ment in selected patients, given
the risks of repeat cardiac sur-
gery, and the practice is now
widely employed (2). However,
clinical outcomes are worse after
SVG PCI than after PCI of native
coronary arteries (3). The saphe-
nous vein graft is more prone to
thrombosis compared with native
coronary arteries, a propensity that
might be mitigated by long-term
dual antiplatelet therapy. Current
practice patterns with regard to antiplatelet therapy in pa-
tients undergoing SVG PCI are informed largely by data
extrapolated from clinical trials and observational studies of
PCI of native coronary arteries.
Although early termination or noncompliance with dual
antiplatelet therapy has been shown to be associated with an
increase in adverse cardiovascular events, including death
and myocardial infarction (MI), the pattern of adverse
events after clopidogrel cessation with longer durations of
therapy remains less clear (4). We hypothesized that dis-
continuation of clopidogrel therapy after SVG PCI, includ-
ing after 1 year of treatment as recommended by current
guidelines, might be associated with a short-term increase in
death or MI.
Methods
Patients. We identified consecutive patients undergoing
SVG PCI at the Regional Cardiac Catheterization labora-
tory located at the Kaiser Permanente Los Angeles Medical
Center from January 1, 2000, to December 31, 2009. Kaiser
Permanente is an integrated pre-paid health plan providing
comprehensive care to more than 3 million members in
Southern California. The health plan owns and operates
medical centers, ambulatory care facilities, pharmacies, and
laboratories. The Regional Cardiac Catheterization labora-
tory serves as the primary referral site for 8 acute care
hospitals in the region.
All patients in the cohort underwent SVG PCI and
received either a drug-eluting (DES) or bare-metal stent
(BMS). The choice of stent type was at the discretion of the
operator. Heparin with or without a glycoprotein IIb/IIIa
inhibitor or bivalirudin was used in all cases. Clopidogrel
300 to 600 mg was administered before PCI. Patients who
had an adverse event while receiving clopidogrel therapy
were excluded in the primary analyses.
Data collection. DEMOGRAPHIC DATA. Baseline demo-
raphic data were obtained for review from patient medical
ecords and health plan databases. For each patient, data on
ge, sex, stent size, stent diameter, site of stent deployment,
ther medical history, and procedural data were obtained
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
IRR  incidence rate ratio
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SVG  saphenous vein
graftrom health plan databases. Laboratory data were obtained vt the time of cardiac catheterization or the most recent
alue before the procedure.
MEDICATION USE. Clopidogrel use was obtained by review
of prescription records through an electronic pharmacy
prescription database. The pharmacy database links all
health plan pharmacies and captures all prescriptions dis-
pensed. Subjects in the study obtained medications from
health plan pharmacies; those without prescription records
available (1.8%) were excluded. The number of prescriptions
filled, the daily dose, and the number of pills dispensed for
each prescription beginning on the day of discharge after
index PCI were used to calculate the duration of clopidogrel
use. All patients received 75 mg daily of clopidogrel post-
PCI. The largest quantity dispensed was 100 tablets, requir-
ing patients to return to the pharmacy for additional
medication. Noncompliance was defined as a gap in clopi-
dogrel therapy of 5 days. In the primary analysis, the last
date of clopidogrel use was based on the date of the last
prescription and number of tablets dispensed.
Adjunctive pharmacotherapy with statins, beta-blockers,
angiotensin-converting enzyme inhibitors, and angiotensin
II receptor blockers were also determined by electronic
pharmacy prescription records. Use of these medications
was defined as 1 or more prescriptions for each drug after
the PCI date. Aspirin use was not available through the
electronic prescription database. Nevertheless, all patients
were instructed to take aspirin 325 mg daily for 90 days and
then 81 mg daily indefinitely, regardless of stent type.
STUDY ENDPOINTS. The primary endpoint of the study was
composite of all-cause mortality or nonfatal MI. Vital
tatus was obtained from the medical records, health plan
atabases, and MORTLINK, which is a validated death
atabase of the residents of California maintained by the
tate. Follow-up MI data were obtained with International
lassification of Disease-9th Revision-Clinical Modifica-
ion codes for MI (410.xx) and at least 1 abnormal cardiac
iomarker (e.g., Troponin I, creatine kinase, or creatine
inase-myocardial band). Patients were censored for loss of
ealth plan membership, a subsequent PCI procedure for an
ndication other than MI, and at the end of the follow-up
eriod. Hospital stays outside the healthcare network were
lso captured through administrative claims data. The
ollow-up period ended January 1, 2010.
Both inpatient and outpatient medical records were
eviewed system-wide by 2 investigators (A.S. and S.B.) for
leeding events (gastrointestinal, intracranial, or other) or
he administration of blood products associated with termi-
ation of clopidogrel therapy and a primary endpoint.
tatistical analysis. Continuous variables were reported as
ean  SD or median and interquartile range if the
istribution was not normally distributed. The Student t test
as used for normally distributed variables, and the Wil-
oxon rank sum test was used for non-normally distributed
ariables. Categorical variables are reported as percentage
b
G
percutaneous coronary intervention; PDA  posterior descending artery; PLV  posterior lateral
branch; RCA  right coronary artery.
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December 11, 2012:2357–63 Clopidogrel Therapy After SVG PCIand absolute values with comparisons made with the chi-
square test or Fisher exact test where appropriate.
A multivariable Cox regression model was constructed to
obtain risk-adjusted instantaneous incidence rates of death
or MI after stopping clopidogrel with kernel hazard func-
tions, including by stent type. The following covariates were
included in the model: age, sex, comorbidities, clopidogrel
duration and noncompliance, stent type and diameter, PCI
period (year of index PCI: early, 2000 to 2004; late, 2005 to
2009), and use of concomitant medications (beta-blockers,
statins, and others). The proportionality assumption was
tested for Schoenfeld residuals and satisfied. Failure plots by
clopidogrel duration and stent type were created according
to the method of Kaplan-Meier. The strata of clopidogrel
duration were compared with the log-rank test.
A piecewise exponential survival model was used to
generate adjusted incidence rate ratios (IRRs) and 95%
confidence intervals (CIs) comparing the 0- to 90-day and
91- to 365-day intervals after clopidogrel cessation. The
independent variable of interest was the risk of adverse
events in the 0- to 90-day interval after clopidogrel cessation
compared with the subsequent 91- to 365-day period. The
covariates included in this model were those noted in the
preceding text. We also used Poisson regression to model
the relationship. The findings were consistent with the
primary results and are not further reported. Adjusted IRR
were calculated for pre-specified subgroups: clopidogrel
duration, sex, diabetes status, PCI period, stent type, and
stent diameter. A p value for interaction was obtained with
first-order interaction terms in the adjusted regression
model.
In pre-specified sensitivity analyses, we excluded patients
with bleeding events associated with clopidogrel cessation to
assess the influence of such events on the primary endpoint.
In a subsequent analysis, we also excluded patients with a
history of gastrointestinal bleeding.
All analyses were performed with STATA statistical
software (version 12, Stata Corp., College Station, Texas).
Kaiser Permanente Southern California Institutional Re-
view Board approval was received with waiver of the
requirement for written informed consent.
Results
Study population. A total of 603 patients underwent SVG
PCI during the study period. Baseline characteristics are
displayed in Table 1. The mean age was 68  10 years, and
18% were female. There were 1.5  0.8 stents/person
implanted in the study cohort. The stent types used were
50% BMS and 50% DES (27% paclitaxel-eluting, 22%
sirolimus-eluting, and 2% everolimus-eluting stents). The
distribution of clopidogrel use post-PCI was as follows: 6
months, 45%; 6 months to 1 year, 14%; 1 year 41%. The
mean duration of clopidogrel therapy after SVG PCI was
270 days (interquartile range, 59 to 900 days). The meanPopulation CharacteristicsTable 1 Population Characteristics
All
(n  603)
Event-Free at
Clopidogrel Cessation
(n  411)
Age, yrs 68 10 68 10
Female 18 (109) 20 (82)
Prior MI 67 (404) 64 (263)
Prior PCI 61 (368) 60 (247)
Risk factors
Smoker 17 (103) 15 (67)
Diabetes mellitus 52 (314) 52 (214)
Hypertension 94 (567) 93 (382)
Hyperlipidemia 93 (561) 91 (374)
Comorbidities
Chronic kidney disease 46 (277) 44 (181)
Heart failure 44 (265) 45 (185)
History of GI bleed 10 (60) 11 (45)
History of stroke 21 (127) 21 (86)
History of COPD 7 (42) 6 (25)
Atrial fibrillation 22 (133) 23 (95)
Body mass index (kg/m2) 28 5 28 5
Clopidogrel duration
6 months 65 (392) 40 (164)
12 months 41 (247) 23 (95)
Other medications
Statins 79 (476) 77 (316)
Beta-blockers 87 (525) 85 (349)
ACEI or ARB 70 (422) 67 (275)
Warfarin 9 (54) 11 (45)
Ranolazine 1 (5) 1 (3)
Angiographic variables
Stents, n 1.5 0.8 1.5 0.8
Mean stent diameter (mm) 3.3 0.5 3.3 0.5
Cumulative stent length (mm) 24 15 23 14
Distal anastomosis of SVG, %
LAD/diagonal 26 (157) 28 (115)
Circumflex/obtuse marginal 38 (229) 38 (156)
RCA/PDA/PLV 31 (187) 30 (123)
Ramus 5 (30) 4 (17)
Stent type
BMS 50 (302) 59 (242)
DES 50 (301) 41 (169)
Intra-aortic balloon pump 2 (12) 1 (4)
Procedure time (min) 70 28 69 28
Race/ethnicity
White 78 (471) 79 (325)
Asian 9 (54) 10 (41)
African-American 9 (54) 8 (33)
Hispanic 4 (24) 3 (12)
Procedure year
2000–2004 59 (356) 71 (292)
2005–2009 41 (247) 29 (119)
Values are mean  SD or % (n).
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; BMS 
are-metal stent(s); COPD  chronic obstructive pulmonary disease; DES  drug-eluting stent(s);
I  gastrointestinal; LAD  left anterior descending; MI  myocardial infarction; PCI 
C
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Clopidogrel Therapy After SVG PCI December 11, 2012:2357–63duration of follow-up after the index SVG PCI was 3.1
years and the median was 3.4 years.
Clopidogrel cessation and outcomes. Among the 603
patients who underwent SVG PCI during the study period,
411 were event-free at the time of clopidogrel cessation and
had discontinued clopidogrel therapy before the study end
date. The characteristics of these patients are also shown in
Table 1. Mean follow-up after stopping clopidogrel treat-
ment was 543 days, and median was 720 days; there were
223,324 person-days of follow-up. The composite primary
endpoint of all-cause mortality or nonfatal MI occurred in
29.7% (n  122) of patients.
The overall incidence rate of death or MI was 0.54 (95%
I: 0.45 to 0.64)/1,000 person-days. Incidence rates for the
- to 90-day, 91- to 365-day, and 1- to 2-year intervals after
lopidogrel cessation are shown in Table 2. The rate of
death or MI was greatest in the first 90 days after stopping
clopidogrel therapy, corresponding to an approximately
2.6-fold increase (IRR: 2.58; 95% CI: 1.64 to 4.07) in the
incidence of death or MI in the first 90 days post-
clopidogrel cessation compared with the subsequent 91 to
365 days. Risk-adjusted instantaneous incidence rates/
person-day for death or MI after stopping clopidogrel are
shown in Figure 1. The risk of an adverse event seems to be
greatest early after cessation of clopidogrel therapy, regard-
less of clopidogrel duration and stent type. The findings of
an increased risk of adverse events associated with the 0 to
90-day interval compared with the 91 to 365-day interval
were similar when death alone was evaluated (IRR: 2.33;
95% CI: 1.32 to 4.11).
We further explored the distribution of adverse events
after clopidogrel cessation by duration of clopidogrel ther-
apy (Fig. 2). Regardless of the duration of therapy, approx-
imately 40% to 60% of the adverse events in the first year
after cessation of clopidogrel occur within the initial 90
days. This relationship was consistent for patients treated
with clopidogrel for 6 months, 6 months to 1 year, 1 to 2
years, or 2 years after SVG PCI. Moreover, the early
hazard associated with stopping clopidogrel therapy was
consistent across multiple subgroups (Table 3). In particu-
lar, there was no significant difference between BMS and
DES for long-term death/MI after clopidogrel cessation
Incidence of Death or MI andDeath After Clopidog el CessationTable 2 Incidence of Death r MI andDeath After Clopidogrel Cessation
Period
At-Risk
(n)
Events
(n)
Incidence Rate/1,000
Patient-Days (95% CI)
Death or MI 0–90 days 411 43 1.26 (0.93–1.70)
91–365 days 358 37 0.41 (0.30–0.56)
1–2 yr 308 40 0.41 (0.30–0.55)
Death 0–90 days 411 25 0.71 (0.48–1.06)
91–365 days 376 26 0.27 (0.18–0.39)
1–2 yr 335 26 0.25 (0.20–0.31)
CI  confidence interval; MI  myocardial infarction.(Fig. 3). The 2-year event rates after clopidogrel cessation inthe BMS and DES groups were 29% and 34%, respectively
(log-rank p  0.45).
In sensitivity analyses, the results were qualitatively sim-
ilar after removing patients with a bleeding event leading to
clopidogrel cessation. There were 8 (1.3%) patients with a
primary endpoint who discontinued clopidogrel therapy
related to a bleeding event. The incidence rates for the 0- to
90-day interval and 91- to 365-day intervals excluding such
patients were 1.25 (95% CI: 0.92 to 1.69) and 0.55 (95% CI:
0.34 to 0.89), respectively; the corresponding IRR was 2.27
(95% CI: 1.90 to 2.68). The results were also qualitatively
similar after removing patients with a history of gastroin-
testinal bleeding, which was noted in 10% of the cohort.
The IRR was 2.30 (95% CI: 1.90 to 2.79) after excluding
patients with a history of gastrointestinal bleeding. We also
calculated the incidence rate for the 0- to 90-day interval
Figure 1 Risk-Adjusted IRR for Death or
Myocardial Infarction After Stopping Clopidogrel
Risk-adjusted incidence rate ratio (IRR) for death or myocardial infarction after
stopping clopidogrel by duration of clopidogrel therapy (A) and stent type (B).
The rate of death or myocardial infarction is greatest in the near term (0 to 90
days) after clopidogrel cessation, regardless of the treatment duration or stent
type. BMS  bare-metal stent(s); DES  drug-eluting stent(s).
2361JACC Vol. 60, No. 23, 2012 Sachdeva et al.
December 11, 2012:2357–63 Clopidogrel Therapy After SVG PCIafter excluding patients with 30 days of clopidogrel
therapy, a group that might be at heightened risk for
noncompliance and therefore adverse events. After exclud-
ing such patients, incidence rates for death or MI at 0 to 90
and 91 to 365 days were 1.12 (95% CI: 0.78 to 1.61) and
Figure 2 Distribution of Events in First Year
After Clopidogrel Cessation
The time interval with the greatest number of events was the initial 90 days
after clopidogrel cessation across a range of different clopidogrel treatment
durations. MI  myocardial infarction; PCI  percutaneous coronary
intervention.
Multivariate Analyses for Selected Subgroups forRisk of Death or MI in 0- to 90-Day Interval AfteClop dogr l Cessatio Compared With Subsequ nt91 to 365 Day
Table 3
Multivariate Analyses for Selected Subgroups for
Risk of Death or MI in 0- to 90-Day Interval After
Clopidogrel Cessation Compared With Subsequent
91 to 365 Days
Cohort N IRR 95% CI
p Value for
Interaction
Overall 411 2.58 1.64–4.07
Sex 0.26
Male 327 2.18 1.29–3.69
Female 84 4.02 1.58–10.25
Diabetes 0.54
Yes 215 2.90 1.61–5.23
No 196 2.15 1.05–4.42
Clopidogrel duration 0.42
6 months 245 2.93 1.62–5.28
6 months 166 2.09 1.02–4.28
PCI period 0.26
2000–2004 120 2.43 1.45–4.05
2005–2009 291 3.11 1.15–8.36
Stent type 0.31
BMS 248 2.09 1.17–3.74
DES 163 3.42 1.63–7.17
Stent diameter 0.32
3.0 mm 175 2.27 1.06–4.83
3.0 mm 236 2.71 1.53–4.79IRR  incidence rate ratios; other abbreviations as in Table 1 and 2.0.44 (95% CI: 0.31 to 0.63), respectively; the corresponding
IRR was 2.05 (95% CI: 1.21 to 3.47).
Clopidogrel duration and outcomes. In secondary analy-
ses, we analyzed the full study cohort (n  603) and
observed that longer duration of clopidogrel therapy was
associated with a lower rate of long-term death or MI
post-PCI (Fig. 4). The cumulative 5-year event rate was
lowest in patients treated with clopidogrel for 2 years
(p 0.001). The event rate at 5 years post-PCI was 54.3%
for 0 to 6 months of clopidogrel therapy, 52.3% for 6
months to 1 year of therapy, 42.7% for 1 to 2 years of
Figure 3 Long-Term Death or Myocardial Infarction
After Clopidogrel Cessation by Stent Type
The events rates were similar between bare-metal (BMS) and drug-eluting
stents (DES) up to 2 years after stopping clopidogrel (log-rank p  0.45).
Figure 4
Long-Term Death or Myocardial Infarction
After Saphenous Vein Graft Percutaneous
Coronary Intervention by Clopidogrel Duration
Kaplan-Meier failure plot for death or myocardial infarction by clopidogrel dura-
tion from the index saphenous vein graft percutaneous coronary intervention.
The event rate seems to increase after clopidogrel cessation. The rate of
death or myocardial infarction is lower with longer duration of clopidogrel post-
percutaneous coronary intervention (log-rank p  0.001).
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log-rank p  0.001). The adjusted hazard ratio for 2
years of clopidogrel therapy compared with 6 months was
0.48 (95% CI: 0.33 to 0.70; p 0.001), corresponding to a
ignificant 52% reduction in death or MI.
iscussion
ittle is known about the role of dual antiplatelet therapy
fter SVG PCI. To our knowledge, this is the first study to
eport on the pattern of adverse events after clopidogrel
essation in patients undergoing SVG PCI. We observed an
ncrease in death and MI shortly after clopidogrel cessation,
egardless of the duration of clopidogrel therapy. The
lustering of events was observed to be greatest 0 to 90 days
fter stopping clopidogrel therapy. There was an approxi-
ately 2.6-fold increase in the incidence of death or MI in
he first 90 days post-clopidogrel cessation, compared with
he subsequent 91 to 365 days. This relationship was
pparent across a broad range of treatment durations.
mong patients treated with clopidogrel for 6 months, 6
months to 1 year, 1 to 2 years, or 2 years, there was a
consistent early hazard with discontinuation of clopidogrel
therapy. Hence, regardless of the treatment duration, approx-
imately 40% to 60% of the adverse events within the first 1 year
after stopping clopidogrel occurred in the first 90 days.
This early hazard of stopping clopidogrel therapy does
not seem to be the result of noncompliance and is less likely
to be the result of confounding events leading to clopidogrel
cessation. In sensitivity analyses, we assessed the impact of
noncompliance by excluding patients with 30 days of
therapy. After excluding such patients, there was a 2-fold
increase in early death or MI, which was qualitatively similar
to the overall result of the primary analysis. One postulated
mechanism that might confound the observed relationship
and could account for the early hazard is bleeding leading to
cessation of clopidogrel therapy. Bleeding events often lead
to a hypercoagulable state and disruption of cardioprotective
medications, including dual antiplatelet therapy, placing the
patient at heightened risk for adverse cardiovascular events.
Also, the need for transfusions might promote a prothrom-
botic state (5). There remained a 2.3-fold increase in the early
hazard of death or MI, qualitatively similar to the full study
cohort, after patients with a concomitant bleeding event
requiring cessation or disruption of clopidogrel therapy were
excluded. The results were also consistent after excluding
subjects with a history of gastrointestinal bleeding and across
several subgroups. In support of our findings, there is evidence
that an early hazard associated with clopidogrel cessation
might exist in PCI of native coronary arteries (6,7).
It is possible that the clustering of events early after
clopidogrel cessation is reflective of the increased potency of
dual antiplatelet therapy at protecting from underlying
thrombotic substrate compared with aspirin alone. After
clopidogrel cessation, this protective effect is no longer
present, which might lead to adverse events. This might bemore evident in populations at high-risk for thrombotic
complications, such as patients undergoing SVG PCI. This
phenomenon might also be mediated by an increase in
platelet reactivity, because some studies have observed an
increase in platelet reactivity after discontinuation of long-
term clopidogrel therapy (8–11). Moreover, withdrawal of
clopidogrel therapy has been associated with a significant
increase in markers of inflammation (8).
Clopidogrel duration. Our results provide insight into the
relationship between duration of clopidogrel therapy and
adverse events, although this is not the primary aim of this
study. To our knowledge, there are no prior reports on this
topic in patients undergoing SVG PCI. These data suggest
that the lowest event rates are observed with longer dura-
tions of clopidogrel therapy with the lowest rates of death or
MI observed with 2 years of treatment. Nevertheless, as
previously noted, even in patients treated for 2 years there
was evidence of an early hazard for death or MI associated
with clopidogrel cessation. In aggregate, these data support
longer durations of dual antiplatelet therapy after SVG PCI.
Study limitations. First, this was an observational analysis,
and clopidogrel use was not randomly assigned. Neverthe-
less, the observation of a consistent early hazard across a
broad range of duration of clopidogrel therapy suggests the
results are not confounded by differences in duration of
therapy, noncompliance, or comorbidity severity. Second,
ascertainment of the exposure, clopidogrel use, was based
upon pharmacy prescription records; pill counts might have
provided a more precise estimate of clopidogrel use. The use
of prescriptions filled has been shown to reflect medication
use by the patient with a high degree of accuracy (12).
Third, aspirin use was not available through the pharmacy
prescription database, and our inability to adjust for aspirin
noncompliance is a limitation. However, all patients re-
ceived the same written instructions with regard to aspirin
therapy. It is very likely that patients refilling clopidogrel
prescriptions were also compliant with aspirin therapy.
Fourth, the patients included in this study were insured and
received care in a large pre-paid health plan. The health
plan membership is representative of the general population
of the state of California except for the socioeconomic
extremes. It is possible that in other populations, particu-
larly the underinsured or non-insured, the observed pattern
of events might be different and the magnitude of the early
hazard associated with clopidogrel cessation might be exag-
gerated. Fifth, details on stent thrombosis or rates of target
vessel revascularization due to MI were not available. Lastly,
clopidogrel was the only adjunctive antiplatelet agent inves-
tigated. These results do not apply to newer antiplatelet
agents such as prasugrel or ticagrelor.
Conclusions
We observed an approximately 2-fold increase in the inci-
dence of death or MI in the initial 0 to 90 days after
clopidogrel cessation compared with the subsequent
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December 11, 2012:2357–63 Clopidogrel Therapy After SVG PCIfollow-up period. This pattern of events was consistent
among patients treated with clopidogrel for 6 months, 6
months to 1 year, 1 to 2 years, or 2 years and in subgroup
nalyses. These data provide new insights into the impor-
ance and possible limitations of dual antiplatelet therapy
fter SVG PCI. Additional studies are needed to identify
reatment strategies and elucidate the mechanisms to ad-
ress this effect.
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